Crossject S.A (ALCJ) | News Based Sentiment Analysis

• On October 1, 2025, Crossject S.A. reported a cash position of €6.3 million as of June 30, 2025, a decrease from €7.0 million on December 31, 2024. This decrease is something investors will be watching closely, but is offset by significant new funding.
• The company secured an impressive €11.3 million in new R&D funding from the American Government in September, following €6.5 million in R&D reimbursements from BARDA in the first half of 2024 – an increase of €3.1 million. This influx of funding is crucial for advancing their ZEPIZURE® EUA application.
• Crossject is making progress towards submitting the Emergency Use Authorization (EUA) application for ZEPIZURE® to BARDA, with BARDA completing mock audits in September 2025 in preparation for potential FDA inspections. This is a key regulatory step for the company.
• On October 1, 2025, Crossject’s stock experienced a significant jump, increasing by 7.73% to trade at €1.950, and later rising to €1.964, an 8.51% increase. This positive market reaction suggests investor confidence in the company’s progress.
• Crossject obtained a new credit line of €750,000 from a new banking partner on October 1, 2025, providing additional financial flexibility. President Patrick Alexandre anticipates a positive result in 2024 if invoicing begins by the end of 2025 or early 2026.

The Investment Story: Crossject is actively securing funding and making regulatory progress with its ZEPIZURE® application, while also experiencing positive market reaction to its operational advancements. The company is focused on achieving a positive result through invoicing in the near future.

What It Means for Investors: The combination of increased funding, positive stock movement, and regulatory steps suggests a strengthening investment case. However, the decreasing cash position requires continued monitoring, and the reliance on timely invoicing for a positive outcome introduces some risk.

Looking Ahead: Investors should watch for updates on the ZEPIZURE® EUA application submission and the start of invoicing, ideally by the end of 2025 or early 2026, as anticipated by President Alexandre. Continued monitoring of the cash position will also be important.

The Bottom Line: October was a positive month for Crossject, marked by significant funding, regulatory progress, and a favorable market response. While the cash position warrants attention, the company appears to be on a promising trajectory with ZEPIZURE®, making it a potentially attractive investment for those following the biopharmaceutical space.